Amneal Pharmaceuticals Inc (AMRX) Stock Price, Quote & News

Company Profile

Amneal Pharmaceuticals, Inc., a global biopharmaceutical company, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Affordable Medicines, Specialty, and AvKARE. The Affordable Medicines segment offers dosage forms and delivery systems, which include immediate and extended-release oral solids, powders, liquids, sterile injectables, nasal sprays, inhalation and r...

Industry: Drug Manufacturers - Specialty & Generic

Sector: Healthcare

Phone: 908 947 3120

Fax: 908 947 3146

Website: www.amneal.com

Address:

400 Crossing Boulevard, 3rd Floor, Bridgewater, United States

10sense Oct. 30 at 5:58 PM

$AMRX great numbers on this one this morning. I have no clue why it's down

0 · Reply

OpenOutcrier Oct. 30 at 12:38 PM

$AMRX (+3.2% pre) Amneal receives tentative FDA approval for generic asthma inhaler https://ooc.bz/l/82505

0 · Reply

BEATOFtheMARKET Oct. 27 at 9:56 PM

Results $AMRX $AMRZ $AMSC $AMT $AMWD 🔥

0 · Reply

resistancebreakers Oct. 2 at 7:23 PM

$AMRX insider buys 🔥🪖🫡☝️

1 · Reply

Fishbull Oct. 1 at 11:11 PM

$AMRX Let’s see how far this will go now that 10$ has been crossed

0 · Reply

Mhollenbuy Sep. 30 at 5:32 PM

$AMRX

0 · Reply

Fishbull Sep. 30 at 1:25 AM

$AMRX hoping it crosses 10$

0 · Reply

POV_NPC Sep. 26 at 9:48 PM

$AMRX growth driver. This company is focused on expansion and is making the case for long term strength. https://finance.yahoo.com/news/amneal-announces-bla-submission-biosimilar-120000008.html

0 · Reply

sandford1 Sep. 26 at 1:41 AM

$AMRX Does anyone know how Pfizer buying metesera pharma impact amneal contract with metesera.

1 · Reply

NyseDayTrader Sep. 24 at 8:58 PM

$HYFT $NVO $AMRX $LLY

0 · Reply

Amneal Pharmaceuticals, Inc. (AMRX) Q3 2025 Earnings Call Transcript

Oct 30, 2025, 6:00 AM EDT - 16 hours ago

Amneal Reports Third Quarter 2025 Financial Results

Oct 29, 2025, 4:05 PM EDT - 1 day ago

Amneal Receives U.S. FDA Tentative Approval for Beclomethasone Dipropionate HFA Inhalation Aerosol

Oct 27, 2025, 8:00 AM EDT - 3 days ago

Amneal Launches Brekiya® – the First and Only DHE Autoinjector for Adults with Migraine With or Without Aura and Cluster Headaches

Sep 30, 2025, 4:05 PM EDT - 4 weeks ago

Amneal to Report Third Quarter 2025 Results on October 30, 2025

Sep 26, 2025, 8:00 AM EDT - 4 weeks ago

Amneal Announces BLA Submission of Biosimilar Candidate to XOLAIR® (omalizumab)

Sep 23, 2025, 8:00 AM EDT - 5 weeks ago

Amneal Receives U.S. FDA Approval for Bimatoprost Ophthalmic Solution, 0.01%

Sep 11, 2025, 8:00 AM EDT - 7 weeks ago

Amneal Receives U.S. FDA Approval of Sodium Oxybate Oral Solution

Sep 11, 2025, 7:23 AM EDT - 7 weeks ago

Amneal Pharmaceuticals: A Large, Diversified Clinical Portfolio That Keeps Growing

Sep 4, 2025, 4:01 PM EDT - 2 months ago

Amneal Receives U.S. FDA Approval for Risperidone Extended-Release Injectable Suspension

Aug 5, 2025, 2:56 PM EDT - 3 months ago

Amneal Pharmaceuticals, Inc. (AMRX) Q2 2025 Earnings Call Transcript

Aug 5, 2025, 7:30 AM EDT - 3 months ago

Knight Therapeutics Announces Regulatory Submission of CREXONT® (Carbidopa and Levodopa) Extended-Release Capsules in Mexico

Aug 5, 2025, 6:00 AM EDT - 3 months ago

Amneal Reports Second Quarter 2025 Financial Results

Jul 21, 2025, 7:39 AM EDT - 3 months ago

Amneal Announces Proposed Refinancing of Existing Credit Agreement, including Private Offering of Senior Secured Notes Due 2032

Jul 21, 2025, 7:38 AM EDT - 3 months ago

Amneal Reports Certain Preliminary Second Quarter 2025 Financial Results

Jul 18, 2025, 7:00 AM EDT - 3 months ago

Knight Therapeutics Announces Filing of New Drug Submission for CREXONT® (Carbidopa and Levodopa) Extended-Release Capsules in Canada

Jul 9, 2025, 8:00 AM EDT - 4 months ago

Amneal to Report Second Quarter 2025 Results on August 5, 2025

Jun 25, 2025, 8:00 AM EDT - 4 months ago

Amneal Highlights Positive Topline Results from Confirmatory Clinical Study of Biosimilar Candidate to XOLAIR(R) (omalizumab), Developed by Kashiv BioSciences

Jun 12, 2025, 8:00 AM EDT - 5 months ago

Amneal Receives U.S. FDA Approval for Prednisolone Acetate Ophthalmic Suspension

May 29, 2025, 4:05 PM EDT - 5 months ago

Amneal to Participate at Upcoming Investor Conferences in June

May 15, 2025, 8:16 AM EDT - 6 months ago

US FDA approves Amneal's migraine treatment

May 15, 2025, 8:00 AM EDT - 6 months ago

Amneal Receives U.S. FDA Approval for Brekiya® (dihydroergotamine mesylate) injection for the Acute Treatment of Migraine and Cluster Headaches in Adults

May 8, 2025, 7:00 AM EDT - 6 months ago

Amneal and Apiject to Expand Sterile and Blow-Fill-Seal (BFS) Capabilities for Advanced Pharmaceutical Manufacturing in the U.S.

May 2, 2025, 11:32 AM EDT - 6 months ago

Amneal Pharmaceuticals, Inc. (AMRX) Q1 2025 Earnings Call Transcript

May 2, 2025, 6:00 AM EDT - 6 months ago

Amneal Reports First Quarter 2025 Financial Results

Apr 11, 2025, 8:00 AM EDT - 7 months ago

Amneal Donates $1.5 Million to Support Patients During Parkinson's Awareness Month

Apr 8, 2025, 4:05 PM EDT - 7 months ago

Amneal to Report First Quarter 2025 Results on May 2, 2025

Apr 7, 2025, 8:00 AM EDT - 7 months ago

Amneal Announces New Data from Phase 3 Study Showing Significant Improvements in Sleep Quality with CREXONT® (Carbidopa and Levodopa) Extended-Release Capsules in Parkinson's Disease

Apr 3, 2025, 8:00 AM EDT - 7 months ago

Amneal Announces Expanded Coverage for CREXONT® (Carbidopa and Levodopa) to Enhance Access for Parkinson's Disease Patients in the U.S.

Apr 1, 2025, 8:00 AM EDT - 7 months ago

Amneal Launches BORUZU™, First Ready-to-Use Bortezomib Injection for Multiple Myeloma and Mantle Cell Lymphoma

Mar 19, 2025, 3:14 PM EDT - 8 months ago

Amneal Pharmaceuticals: Shares Still Feel Significantly Undervalued

Mar 10, 2025, 4:05 PM EDT - 8 months ago

Amneal to Participate at Upcoming Investor Conference

Mar 3, 2025, 4:05 PM EST - 8 months ago

Amneal's BLA Submissions for Two Denosumab Biosimilars Accepted for Review by U.S. FDA

Feb 28, 2025, 2:20 PM EST - 8 months ago

Amneal Pharmaceuticals, Inc. (AMRX) Q4 2024 Earnings Call Transcript

Feb 28, 2025, 6:00 AM EST - 8 months ago

Amneal Reports Fourth Quarter and Full Year 2024 Financial Results

Feb 24, 2025, 1:42 PM EST - 8 months ago

Generic Drug Maker Amneal Pharmaceuticals Is Positioned To Growth Well Ahead Of Peers, Analyst Upgrades Stock

Feb 19, 2025, 8:00 AM EST - 9 months ago

Amneal Launches Mesalamine and Receives U.S. FDA Approval for Lenalidomide

Jan 29, 2025, 8:30 AM EST - 9 months ago

Amneal to Report Fourth Quarter and Full Year 2024 Results on February 28, 2025

Jan 23, 2025, 8:00 AM EST - 10 months ago

Amneal Receives U.S. FDA Approval for Memantine/Donepezil Extended-Release Capsules and Everolimus Tablets for Oral Suspension, and Tentative U.S. FDA Approval for Rifaximin

Dec 4, 2024, 8:00 AM EST - 11 months ago

Amneal to Participate at Upcoming Investor Conferences

Nov 21, 2024, 4:05 PM EST - 1 year ago

Amneal Resubmits DHE Autoinjector New Drug Application and Receives U.S. FDA Approval of Exenatide, its First Generic Injectable GLP-1 Agonist

Nov 8, 2024, 3:27 PM EST - 1 year ago

Amneal Pharmaceuticals, Inc. (AMRX) Q3 2024 Earnings Call Transcript

Nov 8, 2024, 6:00 AM EST - 1 year ago

Amneal Reports Third Quarter 2024 Financial Results

Oct 21, 2024, 8:00 AM EDT - 1 year ago

Amneal Receives U.S. FDA Approval of New Drug Application for Pyridostigmine Bromide Extended-Release Tablets

Oct 8, 2024, 4:05 PM EDT - 1 year ago

Amneal to Report Third Quarter 2024 Results on November 8, 2024

Oct 1, 2024, 6:00 AM EDT - 1 year ago

Amneal and Metsera Announce Strategic Collaboration to Develop and Supply Portfolio of Next-Generation Medicines for Obesity and Metabolic Diseases

Sep 23, 2024, 8:00 AM EDT - 1 year ago

Amneal Launches CREXONT® (Carbidopa and Levodopa) Extended-Release Capsules for Treatment of Parkinson's Disease

Sep 5, 2024, 4:05 PM EDT - 1 year ago

Amneal and Shilpa Announce U.S. FDA Approval of BORUZU™, the First Ready-to-Use Version of Bortezomib for subcutaneous administration

Aug 20, 2024, 9:45 AM EDT - 1 year ago

Melina Kennedy Joins the LDI, Ltd. Board of Managers

WBTN

Aug 20, 2024, 8:00 AM EDT - 1 year ago

Amneal Receives U.S. FDA Approval for Propofol Injectable Emulsion Single Dose Vials

10sense Oct. 30 at 5:58 PM

$AMRX great numbers on this one this morning. I have no clue why it's down

0 · Reply

OpenOutcrier Oct. 30 at 12:38 PM

$AMRX (+3.2% pre) Amneal receives tentative FDA approval for generic asthma inhaler https://ooc.bz/l/82505

0 · Reply

BEATOFtheMARKET Oct. 27 at 9:56 PM

Results $AMRX $AMRZ $AMSC $AMT $AMWD 🔥

0 · Reply

resistancebreakers Oct. 2 at 7:23 PM

$AMRX insider buys 🔥🪖🫡☝️

1 · Reply

Fishbull Oct. 1 at 11:11 PM

$AMRX Let’s see how far this will go now that 10$ has been crossed

0 · Reply

Mhollenbuy Sep. 30 at 5:32 PM

$AMRX

0 · Reply

Fishbull Sep. 30 at 1:25 AM

$AMRX hoping it crosses 10$

0 · Reply

POV_NPC Sep. 26 at 9:48 PM

$AMRX growth driver. This company is focused on expansion and is making the case for long term strength. https://finance.yahoo.com/news/amneal-announces-bla-submission-biosimilar-120000008.html

0 · Reply

sandford1 Sep. 26 at 1:41 AM

$AMRX Does anyone know how Pfizer buying metesera pharma impact amneal contract with metesera.

1 · Reply

NyseDayTrader Sep. 24 at 8:58 PM

$HYFT $NVO $AMRX $LLY

0 · Reply

mikesterz7 Sep. 24 at 12:48 AM

$AMRX The New Jersey-headquartered company said the most common adverse reaction associated with the use of eyedrops is conjunctival hyperemia or redness of the eye. The company expects the solution to be a key growth driver for its Affordable Medicines portfolio.

0 · Reply

prismmarketview Sep. 23 at 6:31 PM

FDA approval: 3AmnealPharma (Nasdaq: $AMRX) wins ANDA for bimatoprost ophthalmic solution 0.01%, the generic equivalent of LUMIGAN®. Expands its Affordable Medicines portfolio, delivering lower-cost treatment for glaucoma & ocular hypertension patients. https://prismmarketview.com/fda-approves-amneals-generic-version-of-bimatoprost-ophthalmic-solution/

0 · Reply

StocktwitsNews Sep. 23 at 12:29 PM

Amneal Pharma Stock Rises On FDA Approval For Generic Version Of AbbVie’s Eyedrops $AMRX https://stocktwits.com/news/equity/markets/amneal-pharma-stock-rises-on-fda-approval-for-generic-version-of-abbvie-eyedrops/chDhHHIR35Q

0 · Reply

notreload_ai Sep. 23 at 12:26 PM

$AMRX has received FDA approval for a generic eye drop (bimatoprost 0.01%) used to treat high eye pressure linked to glaucoma and ocular hypertension. https://notreload.xyz/amneal-generic-bimatoprost-ophthalmic-solution-fda-approved/

0 · Reply

ChristopherBrecher Sep. 22 at 6:25 PM

$AMRX Right now the SEC is "looking the other way" on insider trading. We can use that to our advantage by looking for unusual option activity. Here is one today.

0 · Reply